Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giselle Abangma

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Medical Decision Making : an International Journal of the Society for Medical Decision Making|December 18, 2025
Uncertainty around Health State Values Used in Cost-Effectiveness Analysis: How It Arises and How to Deal with ItDavid Parkin, Andrew Briggs, Giselle Abangma, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 8, 2009
Costs and health utilities associated with extremely preterm birth: evidence from the EPICure studyStavros Petrou, Giselle Abangma, Samantha Johnson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2010
Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trialStavros Petrou, Helen Dakin, Giselle Abangma, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 18, 2024
Reporting Uncertainty Around Health-State Values: A Standard Method and Worked ExampleNancy J Devlin, Giselle Abangma, Andrew Lloyd, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 25, 2026
An Overdue Denunciation of the Minimal Important Difference When Applied to Health State ValuesDavid G T Whitehurst, Andrew Briggs, Andrew J Lloyd, et al.
BMJ Open|August 1, 2014
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trialHelen A Dakin, Sarah Wordsworth, Chris A Rogers, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Medical Decision Making : an International Journal of the Society for Medical Decision Making|December 18, 2025
Uncertainty around Health State Values Used in Cost-Effectiveness Analysis: How It Arises and How to Deal with ItDavid Parkin, Andrew Briggs, Giselle Abangma, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 8, 2009
Costs and health utilities associated with extremely preterm birth: evidence from the EPICure studyStavros Petrou, Giselle Abangma, Samantha Johnson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2010
Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trialStavros Petrou, Helen Dakin, Giselle Abangma, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 18, 2024
Reporting Uncertainty Around Health-State Values: A Standard Method and Worked ExampleNancy J Devlin, Giselle Abangma, Andrew Lloyd, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 25, 2026
An Overdue Denunciation of the Minimal Important Difference When Applied to Health State ValuesDavid G T Whitehurst, Andrew Briggs, Andrew J Lloyd, et al.
BMJ Open|August 1, 2014
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trialHelen A Dakin, Sarah Wordsworth, Chris A Rogers, et al.
Pageof 1